News | | More »

Aktiespararna: Analysis Active Biotech: "Effektsignal i fas 1" (in Swedish)

Equity research and Presentations

Active Biotech’s partner NeoTX to Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Press Release

New preclinical data on tasquinimod will be presented at the annual meeting of American Society of Hematology (ASH)

Press Release

Active Biotech Interim report January - September 2021

Press Release

Active Biotech and NeoTX today announce that the first patient has been enrolled in the phase IIa clinical trial of naptumomab estafenatox in combination with docetaxel in patients with advanced non-small cell lung cancer (NSCLC)

Press Release

Tasquinimod clinical development in multiple myeloma advances into combination therapy following completion of the initial phase of the ongoing trial in the US

Press Release

Active Biotech presentation at Aktiespararnas “Aktiedag Lund” (in Swedish)

Equity research and Presentations

Analys Active Biotech: Ny plan för ögonstudie (in Swedish)

Equity research and Presentations

Active Biotech provides status update of its clinical naptumomab project

Press Release

Annual Report 2020 Active Biotech AB (publ)

Annual Reports

An Experienced Team with Extensive Knowledge in Drug Development

Management

Clinical Study in Uveitis to Start During 2021

Laquinimod

Novel Treatment of the Blood Cancer Multiple Myeloma

Tasquinimod

We Develop New Treatments for Cancer and Inflammatory Diseases

We leverage our extensive knowledge and previously generated documentation on our assets to develop novel treatments for specialist indications with high medical need and commercial value within cancer and inflammatory eye disorders. We have a stringent focus on our projects in multiple myeloma, uveitis and in solid tumors for naptumomab in partnership with NeoTX.

Novel treatments for specialist indications

Pipeline

Disease Area
Discovery
Preclinical
Phase I
Phase II
Phase III
Partner
Cancer
Naptumomab Combination with anti-PDL1 (durvalumab) in solid tumors
Naptumomab Combination with docetaxel in non-small cell lung cancer*
Tasquinimod Multiple myeloma**
Inflammation
Laquinimod Uveitis
Study ongoing
Preparation for study start
* In an academic partnership with the Abramson Cancer Center, Philadelphia, University of Pennsylvania

Our project portfolio comprises small, orally active immunomodulatory molecules as well as antibody-based immunotherapy. We have three projects in our project portfolio, Tasquinimod, Laquinimod and Naptumomab. Read more about Active Biotechs projects »

Uveitis can Lead to Severe Eye Problems Including Blindness

Laquinimod

Multiple Myeloma a Blood Cancer with Unmet Medical Need

Tasquinimod